Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Medical Minute on Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP

In this case example, learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
person default
Jason Schafer, PharmD, MPH
Released: February 8, 2022

Information on this Educational Activity

Faculty

Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Jason Schafer, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Merck and ViiV.

Program Medium

This program has been made available online.

Related Content

Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Christopher Fox, MSN, RN, ANP-BC, AAHIVS
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2022 Expired: June 13, 2023

Dr Michelle Collins-Ogle and Clinical Care Options (CCO): HIV postexposure prophylaxis is recommended following a potential sexual exposure.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Clinical Care Options (CCO): expert commentary on major findings from EPIC-NSW and next steps in PrEP strategies and populationwide HIV prevention efforts

Prof. Don Smith Released: March 18, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): There are key management considerations for patients initiating LA cabotegravir for PrEP

person default Jason Schafer, PharmD, MPH Released: March 15, 2022
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings